 Biopharma Kamada Ltd KMDA has announced that the initial vials of its plasma-derived immunoglobulin IgG product for Covid-19 have received the green light for compassionate use in Israel.The company has now completed manufacturing of the first batch of its plasma-derived IgG product, using its approved proprietary IgG platform technology, and additional production is ongoing.In addition, Kamadas proposed clinical protocol for a Phase 12 clinical trial was submitted to the Israeli Ministry of Health, and the company expects to initiate the study during the third quarter of this year.To expand its clinical development program to the U.S., Kamada is working with Kedrion Biopharma. The companies intend to hold a pre-Investigational New Drug pre-IND meeting with the U.S. Food and Drug Administration FDA early in the third quarter in order to obtain FDAs acceptance of the proposed clinical development program.Kedrion is currently collecting Covid-19 convalescent plasma from U.S. recovered patients at 23 FDA-approved centers across the United States that will be used by Kamada to manufacture additional batches of the product.We believe that Kamada and Kedrion, two leaders in plasma-derived protein therapeutics, are uniquely positioned to make a positive impact in the treatment of COVID-19 patients commented Amir London, Kamadas CEO. To the best of our knowledge, Kamada is the first company globally to complete manufacturing of a plasma-derived IgG product for the treatment of COVID-19.Shares in Kamada are currently trading up 23 year-to-date, and are rising in Wednesdays pre-market trading. The stock has a Moderate Buy consensus with recent buy ratings from HC Wainwright and Jefferies. See KMDA stock analysis on TipRanksHC Wainwrights Andrew Fein recently reiterated his bullish stance on Kamada, citing the companys alpha-1 antitrypsin AAT program. We continue to believe the inhaled formulation could offer a potentially preferable means of delivery compared to Glassia, the companys intravenous IV therapy for AATD patients he explained. Feins 11 price target indicates further upside potential of 31.Related News: Fulgent Pops 18 In After-Market On FDA Nod For Covid-19 Home Test Chembio Sinks 59 In Pre-Market As FDA Revokes Its Covid-19 Test; Top Analyst Cuts Rating Israel Is Said To Be In Talks To Buy Modernas Covid-19 Vaccine Candidate More recent articles from Smarter Analyst: Chembio Sinks 59 In Pre-Market As FDA Revokes Its Covid-19 Test; Top Analyst Cuts Rating HSBC Resumes Plans To Cut 35,000 Jobs Postponed By Pandemic DraftKings Drops 7 In Pre-Market Amid Public Share Offering Oracle Sinks Post-Earnings As Cloud Push Drags On 